Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
344.75
-2.32 (-0.67%)
At close: Jan 23, 2026, 4:00 PM EST
344.69
-0.06 (-0.02%)
After-hours: Jan 23, 2026, 7:31 PM EST
Amgen Employees
Amgen had 28,000 employees as of December 31, 2024. The number of employees increased by 1,300 or 4.87% compared to the previous year.
Employees
28,000
Change (1Y)
1,300
Growth (1Y)
4.87%
Revenue / Employee
$1,284,679
Profits / Employee
$250,179
Market Cap
185.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
| Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
| Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
| Dec 31, 2021 | 24,200 | -100 | -0.41% |
| Dec 31, 2020 | 24,300 | 900 | 3.85% |
| Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
| Dec 31, 2018 | 21,500 | 700 | 3.37% |
| Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
| Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
| Dec 31, 2015 | 17,900 | 0 | - |
| Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
| Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
| Dec 31, 2012 | 18,000 | 200 | 1.12% |
| Dec 31, 2011 | 17,800 | 400 | 2.30% |
| Dec 31, 2010 | 17,400 | 200 | 1.16% |
| Dec 31, 2009 | 17,200 | 300 | 1.78% |
| Dec 31, 2008 | 16,900 | -600 | -3.43% |
| Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
| Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
| Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
| Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
| Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
| Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
| Dec 31, 2001 | 7,700 | 400 | 5.48% |
| Dec 31, 2000 | 7,300 | 900 | 14.06% |
| Dec 31, 1999 | 6,400 | 900 | 16.36% |
| Dec 31, 1998 | 5,500 | 192 | 3.62% |
| Dec 31, 1997 | 5,308 | 662 | 14.25% |
| Dec 31, 1996 | 4,646 | 600 | 14.83% |
| Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| GSK plc | 68,629 |
AMGN News
- 2 days ago - Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential - Seeking Alpha
- 4 days ago - Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access - Business Wire
- 9 days ago - Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing - Barrons
- 10 days ago - Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses - Benzinga
- 11 days ago - Amgen CEO says weight loss drug can address 'patient persistence issue' - CNBC
- 11 days ago - Ro partners with Amgen to study barriers to obesity care, GLP-1 access - Reuters
- 11 days ago - Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Amgen says MariTide helped trial patients maintain weight loss - Reuters